產(chǎn)品[
人乳腺導(dǎo)管瘤細(xì)胞
]資料
如果您對該產(chǎn)品感興趣的話,可以
產(chǎn)品名稱:
人乳腺導(dǎo)管瘤細(xì)胞
產(chǎn)品型號:
CRL-1897
產(chǎn)品廠商:
美國標(biāo)準(zhǔn)生物品收藏中心（ATCC）
產(chǎn)品文檔:
無相關(guān)文檔
簡單介紹
CRL-1897 UACC 812 人乳腺導(dǎo)管瘤細(xì)胞，原代細(xì)胞|細(xì)胞系|細(xì)胞株|菌種；細(xì)胞庫管理規(guī)范，提供的細(xì)胞株背景清楚，提供參考文獻(xiàn)和培養(yǎng)條件！
人乳腺導(dǎo)管瘤細(xì)胞
的詳細(xì)介紹
CRL-1897 UACC 812 人乳腺導(dǎo)管瘤細(xì)胞
|
|
CRL-1897?
|
|
$407.00
|
|
|
UACC-812
|
|
|
A Liebovitz, J Trent
|
|
Biosafety Level:
|
1
|
|
|
frozen
|
|
|
See Propagation
|
|
|
adherent
|
|
|
Homo sapiens (human)
|
|
|
epithelial
|
|
|
Organ: mammary gland; breast
Disease: ductal carcinoma
|
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
|
The breast carcinoma UACC-812 was deposited in the ATCC by Albert Leibovitz and Jeffrey M. Trent, Arizona Cancer Center, University of Arizona, Tucson, Arizona. The cells are distributed for research purposes only. The University of Arizona has released the line subject to the following: 1. UACC-812 or their products MUST NOT BE DISTRIBUTED to third parties. Commercial interests are the exclusive property of the University of Arizona. 2. Any proposed commercial use of these cells must first be negotiated with the Director of the Arizona Cancer Center, University of Arizona, 1501 N. Campbell Avenue, Tucson, Arizona 85724. Telephone (602) 626-7925, FAX (602) 626-2284. 3. In all papers reporting any use of these of these cells or derived products, a direct reference will be made to the original publication given above.
|
|
|
Isolation date: 1986
|
|
|
estrogen receptor
progesterone receptor
|
|
|
range = 58 to 64; abnormal banding region in 3p
|
|
|
43 years
|
|
|
female
|
|
|
ATCC complete growth medium: Leibovitz's L-15 medium with 2 mM L-glutamine supplemented with 20 ng/ml human EGF and 20% fetal bovine serum
Atmosphere: air,
Temperature: 37.0°C
Growth conditions: The cells grow very slowly, and growth is enhanced by using 20% fetal bovine serum and adding epidermal growth factor (20 ng/ml) to the medium.
|
|
|
Protocol:
-
Remove and discard culture medium.
-
Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
-
Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
-
Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
-
Add appropriate aliquots of the cell suspension to new culture vessels.
-
Incubate cultures at 37°C.
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:3 is recommended
Medium Renewal: Every 2 to 3 days
|
|
|
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
|
|
|
100 hrs
|
|
|
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2008
recommended serum:ATCC 30-2020
purified DNA:ATCC 45534
purified DNA:ATCC 45535
purified DNA:ATCC CRL-1897D
|
|
|
22207: . . Proc. Am. Assoc. Cancer Res. 29: 24, 1988.
26165: Meltzer P, et al. Establishment of two new cell lines derived from human breast carcinomas with HER-2/neu amplification. Br. J. Cancer 63: 727-735, 1991. PubMed: 1674877
|
|
